• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    SC 13G/A 1 ea0207102-13ga1maxpro_apollo.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 1)*

     

    Apollomics Inc.

    (Name of Issuer)

     

    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G0411D107

    (CUSIP Number)

     

    May 8, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G/A Page 2 of 4

     

    (1)

    NAMES OF REPORTING PERSON

     

    Maxpro Investment Co., Ltd

    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
       
      (a) ☐
      (b) ☐
    (3) SEC USE ONLY
       
       
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    (5) SOLE VOTING POWER
       
      10,577,029 (1)
    (6) SHARED VOTING POWER
       
      0
    (7) SOLE DISPOSITIVE POWER
       
      10,577,029 (1)
    (8) SHARED DISPOSITIVE POWER
         
        0

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,577,029 (1)
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
      9.70% (2)
    (12) TYPE OF REPORTING PERSON
       
      FI

     

    (1) Maxpro Investment Co., Ltd may be deemed to beneficially own 10,577,029 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) of Apollomics Inc. (the “Issuer”), consisting of (i) 10,194,634 Class A Ordinary Shares and (ii) 382,395 Class A Ordinary Shares issuable upon exercise of warrants exercisable within 60 days of the date of this filing.
    (2) On April 24, 2024, the Issuer had 89,495,790 Class A Ordinary Shares issued and outstanding, as reported in the Issuer’s Rule 424(b)(3) Prospectus, filed with the Securities and Exchange Commission (the “SEC”) on April 24, 2024. On May 8, 2024, the Issuer issued 19,166,666 Class A Ordinary Shares in a private placement with certain accredited investors. Calculations are based on a total of 108,662,456 Class A Shares issued and outstanding as of the date of this filing.

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G/A Page 3 of 4

     

    Explanatory Note

     

    Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 to Schedule 13G (this “Amendment”) amends and supplements the Schedule 13G originally filed with the SEC by Maxpro Investment Co., Ltd (the “Reporting Person”) on May 20, 2024 (the “Original Schedule 13G”) regarding the Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”), of Apollomics Inc. (the “Issuer”). Except as set specifically amended by this Amendment, all items in the Original Schedule 13G remain unchanged.

     

    Item 4. Ownership:

     

    Information with respect to the beneficial ownership of securities of the Reporting Person, is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

     

    As reported in the cover page to this report, the ownership information with respect to the Reporting Person is as follows:

     

    (a)Amount Beneficially Owned: See line 9 of page 2.

     

    (b)Percent of Class: See line 11 of page 2.

     

    (c)Number of Shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: See line 5 of page 2.

     

    (ii)Shared power to vote or to direct the vote: See line 6 of page 2.

     

    (iii)Sole power to dispose or to direct the disposition of: See line 7 of page 2.

     

    (iv)Shared power to dispose or to direct the disposition of: See line 8 of page 2.

     

    As of the date of this filing, the Reporting Person may be deemed to beneficially own 10,577,029 Class A ordinary Class A Ordinary Shares, consisting of (i) 10,194,634 Class A Ordinary Shares and (ii) 382,395 Class A Ordinary Shares issuable upon exercise of warrants exercisable within 60 days of the date of this filing, constituting approximately 9.70% of the issued and outstanding Class A Ordinary Shares of the Issuer (the “Shares”).

     

    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Person, or any of its subsidiaries or affiliates, is or are the beneficial owners of the Shares for any other purpose than Section 13(d) and 13(g) of the Act, as amended.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to an investment company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     

     

     

    CUSIP No. G0411D107 Schedule 13G/A Page 4 of 4

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct.

     

    Date: May 30, 2024

     

      /s/ Yi Kuei Chen
      Name:  Yi Kuei Chen
      Title: Director

     

     

     

     

    Get the next $APLM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

    FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notify

    10/15/25 2:36:10 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Resumes Trading in Apollomics Inc.

    NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively, on October 15, 2025. Trading in the company's Class A ordinary shares and warrants was halted on September 17, 2025 at 2:37:17 p.m. Eastern Time. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web site. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq Media Con

    10/14/25 4:05:00 PM ET
    $APLM
    $NDAQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    SEC Filings

    View All

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    10/15/25 8:24:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    10/14/25 3:30:32 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    9/25/25 5:01:38 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Leadership Updates

    Live Leadership Updates

    View All

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    8/15/24 4:38:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    SC 13G/A - Apollomics Inc. (0001944885) (Subject)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    5/22/24 7:32:01 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Financials

    Live finance-specific insights

    View All

    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

    Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

    3/28/24 7:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

    FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

    3/26/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

    Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

    9/28/23 4:17:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care